Financials data is unavailable for this security.
View more
Year on year Keros Therapeutics Inc had net income fall 46.15% from a loss of 104.68m to a larger loss of 152.99m despite a -- increase in revenues from 0.00 to 151.00k.
| Gross margin | -- |
|---|---|
| Net profit margin | -27,890.94% |
| Operating margin | -31,341.63% |
| Return on assets | -40.10% |
|---|---|
| Return on equity | -43.82% |
| Return on investment | -42.23% |
More ▼
Cash flow in USDView more
In 2023, Keros Therapeutics Inc increased its cash reserves by 18.54%, or 51.98m. Cash Flow from Financing totalled 178.96m or 118,513.91% of revenues. In addition the company used 124.51m for operations while cash used for investing totalled 2.46m.
| Cash flow per share | -5.17 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 13.57 |
|---|---|
| Tangible book value per share | 13.57 |
More ▼
Balance sheet in USDView more
| Current ratio | 19.03 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
